Takeda to Present Broad Range of Clinical Data During 58th American Society of Hematology ...

– Demonstrating Expertise and Leadership in Hematologic Oncology, Presentations Include Phase 3 Data on ADCETRIS^® (brentuximab vedotin) in CD30-Positive Cutaneous T-Cell Lymphoma, NINLARO^TM (ixazomib) in Relapsed/Refractory Multiple Myeloma and Emerging Pipeline –

– Presentations Underscore Takeda's Ongoing Commitment to Transform Care for Patients Affected by Blood Cancers –

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited http://me-newswire.net//news/18984/en...